RxDoctor Payments Data

Catherine Vanvoorn, MD

Internal Medicine · Columbia, MONPI 1720054448

Payments from drug & device makers

$217in general payments, 2019–2025

Across 3 payments — averaging $72.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axsome Therapeutics, Inc.$119
  • Neurocrine Biosciences, Inc.$71
  • Sunovion Pharmaceuticals Inc.$27

What the payments were for

  • Food & beverage$217100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$217 in reported general payments places this provider in the 50th percentile of 2,097 internal medicine providers in Missouri.

See all internal medicine providers in Missouri

Medicare billing

Part B allowed, 2024
$353,836
Medicare patients
741
Services billed
5,484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban1,802$510,086
Invega SustennaPaliperidone Palmitate126$403,682
IngrezzaValbenazine Tosylate18$136,732
XareltoRivaroxaban486$133,756
BetaseronInterferon Beta-1b11$114,322
JardianceEmpagliflozin323$99,217
AustedoDeutetrabenazine30$95,008
XifaxanRifaximin59$86,223
Abilify MaintenaAripiprazole26$77,267
AristadaAripiprazole Lauroxil22$67,007
EntrestoSacubitril/Valsartan169$56,266
RexultiBrexpiprazole66$50,070
FarxigaDapagliflozin Propanediol169$48,665
OzempicSemaglutide44$46,303
Trelegy ElliptaFluticasone/Umeclidin/Vilanter73$44,115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Neurocrine Biosciences, Inc.Ingrezza$71$136,73218 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 2,097 internal medicine providers in Missouri.

Other internal medicine in Columbia

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →